文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

设定基线:在实施肿瘤医生介导的遗传检测之前,对浆液性卵巢癌转诊率和结局进行的 7 年回顾。

Setting a baseline: A 7-year review of referral rates and outcomes for serous ovarian cancer prior to implementation of oncologist mediated genetic testing.

机构信息

Familial Cancer Clinic, Princess Margaret Cancer Centre - University Health Network, Toronto, Canada; Department of Molecular Genetics, University of Toronto, Toronto, Canada.

Familial Cancer Clinic, Princess Margaret Cancer Centre - University Health Network, Toronto, Canada; Department of Molecular Genetics, University of Toronto, Toronto, Canada.

出版信息

Gynecol Oncol. 2020 Aug;158(2):440-445. doi: 10.1016/j.ygyno.2020.05.014. Epub 2020 Jun 3.


DOI:10.1016/j.ygyno.2020.05.014
PMID:32505554
Abstract

OBJECTIVE: Despite guidelines recommending that all women with invasive serous ovarian cancer (SOC) are offered genetic testing, published referral and testing rates have been poor. Many centers have implemented novel genetic counseling service delivery models to increase testing rates. In light of increased awareness and implementation of small process changes at our center, this study aims to establish baseline referral rates and testing outcomes prior to diverging from the traditional model of care. METHODS: A list of women diagnosed with SOC at Princess Margaret Cancer Center (PM) between 2010 and 2016 was obtained from the PM Cancer Registry and cross-referenced against the genetics database to determine referral rates and outcomes of genetic testing. RESULTS: Of 724 women with SOC, 68% were referred for genetic counseling, with an overall testing rate of 61%. Higher referral rates were seen among women with younger ages at diagnosis and high-grade tumors. Of women tested, 22% were found to have a pathogenic variant in BRCA1/2 and 9% in another cancer gene. Notably, 24% of women with a pathogenic variant reported no family history of breast or ovarian cancer. CONCLUSION: Genetic counseling referral and testing rates for women with SOC are higher than previously reported, yet barriers to referral remain. To maximize genetic testing rates and address increasing patient volumes, clinics may be faced with integrating novel genetic counseling delivery models. Findings from this study may serve as a more accurate baseline to which large scale service delivery changes can be compared.

摘要

目的:尽管指南建议所有浸润性浆液性卵巢癌(SOC)患者都应接受基因检测,但发表的转诊和检测率一直很低。许多中心已经实施了新的遗传咨询服务提供模式,以提高检测率。鉴于我们中心的意识提高和小的流程改变的实施,本研究旨在确定传统护理模式偏离之前的转诊率和检测结果基线。

方法:从 PM 癌症登记处获得了 2010 年至 2016 年在 Princess Margaret Cancer Center(PM)诊断为 SOC 的女性名单,并与遗传学数据库交叉引用,以确定遗传咨询的转诊率和基因检测的结果。

结果:在 724 名 SOC 女性中,68%被转诊接受遗传咨询,总体检测率为 61%。诊断年龄较小和肿瘤分级较高的女性转诊率较高。在接受测试的女性中,22%发现 BRCA1/2 中有致病性变异,9%在另一个癌症基因中有致病性变异。值得注意的是,24%有致病性变异的女性报告没有乳腺癌或卵巢癌家族史。

结论:SOC 女性的遗传咨询转诊和检测率高于以往报道,但转诊仍存在障碍。为了最大限度地提高基因检测率并解决不断增加的患者数量,诊所可能需要整合新的遗传咨询服务提供模式。本研究的结果可以作为更准确的基线,与大规模服务提供的变化进行比较。

相似文献

[1]
Setting a baseline: A 7-year review of referral rates and outcomes for serous ovarian cancer prior to implementation of oncologist mediated genetic testing.

Gynecol Oncol. 2020-8

[2]
Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system.

Gynecol Oncol. 2020-9

[3]
testing in women with high-grade serous ovarian cancer: gynecologic oncologist-initiated testing compared with genetics referral.

Int J Gynecol Cancer. 2020-11

[4]
Keeping it simple: genetics referrals for all invasive serous ovarian cancers.

Gynecol Oncol. 2013-5-22

[5]
Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing.

Int J Gynecol Cancer. 2016-6

[6]
Referral patterns for genetic counselling of women diagnosed with tubo-ovarian or peritoneal high-grade serous carcinoma (HGSC) within the Auckland Gynaecological Oncology Centre.

Aust N Z J Obstet Gynaecol. 2019-6

[7]
The sooner the better: Genetic testing following ovarian cancer diagnosis.

Gynecol Oncol. 2015-4-11

[8]
gene testing in women with high-grade serous ovarian carcinoma.

J Obstet Gynaecol. 2021-8

[9]
A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.

BMC Cancer. 2018-3-5

[10]
Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.

Int J Gynecol Cancer. 2019-11-7

引用本文的文献

[1]
Improving Access to Hereditary Testing in Pancreatic Ductal Carcinoma.

JCO Precis Oncol. 2024-8

[2]
A mainstreaming oncogenomics model: improving the identification of Lynch syndrome.

Front Oncol. 2023-5-26

[3]
Theory Designed Strategies to Support Implementation of Genomics in Nephrology.

Genes (Basel). 2022-10-21

[4]
Understanding the Experience of Canadian Women Living with Ovarian Cancer through the Every Woman Study.

Curr Oncol. 2022-5-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索